About
Conceivable Life Sciences is a pioneering biotech company tackling the global infertility crisis through its flagship product, AURA—the world's first AI-powered automated IVF laboratory system. With 18% of adults affected by infertility and 95% unable to access IVF due to cost and availability barriers, Conceivable is engineering a 40-fold scale-up in treatment capacity through full lab automation. AURA integrates six specialized workstations to automate all core IVF lab functions: dish preparation, sperm processing, egg discovery and preparation, intracytoplasmic sperm injection (ICSI), incubation, vitrification, and thawing. Operating at the microscopic level with AI, computer vision, robotics, and advanced optics, AURA delivers the precision of single-cell surgery consistently and at scale—executing the approximately 1.3 billion steps projected across 6.5 million annual global IVF cycles by 2034. A native track-and-trace system digitally identifies every specimen throughout the process, ensuring unprecedented patient safety and full accountability. In an IRB-approved proof-of-concept study, AURA prototypes achieved 21 pregnancies at success rates comparable to the world's top fertility clinics. AURA is currently in clinical operations in Mexico City, including a 100-patient IRB-approved validation study. Backed by a $50M Series A, Conceivable targets fertility clinic partners seeking to eliminate large capital expenditures while dramatically improving throughput, consistency, and outcomes—ultimately making IVF accessible to millions of prospective parents worldwide.
Key Features
- Full IVF Lab Automation via AURA: Six integrated workstations automate every IVF lab function including dish preparation, sperm processing, egg discovery, ICSI, incubation, vitrification, and thawing.
- AI & Computer Vision Precision: Leverages AI, robotics, advanced optics, and machine vision to perform microscopic single-cell operations with superhuman consistency and accuracy.
- Native Track-and-Trace Safety: Every specimen is digitally identified and tracked throughout the entire process, ensuring complete accountability and unprecedented patient safety.
- Clinically Validated Outcomes: IRB-approved proof-of-concept study achieved 21 pregnancies with success rates comparable to the world's top-performing fertility clinics.
- Cost-Reducing Economic Model: Eliminates major CapEx and reduces OpEx for clinical partners through automation, enabling disruptive pricing models that improve patient access.
Use Cases
- Fertility clinics deploying AURA to automate their IVF laboratory workflows and increase patient throughput without proportional staff increases.
- Healthcare networks seeking to expand IVF access to underserved populations by dramatically reducing the cost per cycle through lab automation.
- Academic and research institutions studying embryology and reproductive medicine using AURA's precise, reproducible automated processes for clinical research.
- Fertility clinic operators in high-demand markets looking to scale to thousands of cycles annually while maintaining top-tier success rates and specimen safety.
- Investors and health systems evaluating disruptive models to address the global infertility treatment gap affecting an estimated 20 million prospective patients.
Pros
- Massively Scalable Fertility Care: Automation enables the 40-fold increase in IVF capacity needed to meet actual global demand of ~20 million patients annually.
- Clinically Proven Performance: Real-world results from IRB-approved studies demonstrate success rates on par with the world's best fertility clinics.
- Enhanced Patient Safety: Digital specimen identification and full traceability throughout the process minimizes human error and maximizes accountability.
- Significant Cost Reduction for Partners: Automation-driven CapEx and OpEx savings allow fertility clinics to offer more competitive, accessible pricing to patients.
Cons
- Early-Stage Clinical Availability: Currently limited to clinical operations in Mexico City; broader commercial US rollout is still in progress following Series A funding.
- Enterprise-Only Access: AURA is a B2B system targeting fertility clinic partners—individual patients or small practices cannot directly purchase or access it independently.
- Regulatory and Adoption Complexity: Medical device regulatory approvals across different markets and clinical partner adoption cycles may slow the pace of global expansion.
Frequently Asked Questions
What is AURA?
AURA is Conceivable Life Sciences' flagship product—the world's first AI-powered automated IVF laboratory system. It integrates six workstations to automate all core IVF lab functions using AI, robotics, advanced optics, and machine vision.
Has AURA been used in real clinical settings?
Yes. AURA is currently in clinical operations in Mexico City, including an IRB-approved 100-patient validation study. An earlier proof-of-concept study using AURA prototypes resulted in 21 pregnancies with success rates comparable to the world's top fertility clinics.
How does AURA improve on traditional IVF lab processes?
Traditional IVF labs rely heavily on manual processes that are difficult to scale, prone to human error, and expensive. AURA automates the entire lab workflow with precision beyond human capability, improves consistency and safety through digital traceability, and reduces both capital and operational costs for clinics.
Who are Conceivable Life Sciences' customers?
Conceivable targets fertility clinic operators and healthcare networks as clinical partners who license or deploy AURA to automate their IVF lab operations and improve patient outcomes.
How much funding has Conceivable Life Sciences raised?
Conceivable Life Sciences raised a $50 million Series A round to fund the US commercial launch of AURA and continued expansion of its automated IVF lab platform.
